MA39450B2 - Sels pharmaceutiquement acceptables d'énantiomères de pirlindole s'utilisant en médecine - Google Patents
Sels pharmaceutiquement acceptables d'énantiomères de pirlindole s'utilisant en médecineInfo
- Publication number
- MA39450B2 MA39450B2 MA39450A MA39450A MA39450B2 MA 39450 B2 MA39450 B2 MA 39450B2 MA 39450 A MA39450 A MA 39450A MA 39450 A MA39450 A MA 39450A MA 39450 B2 MA39450 B2 MA 39450B2
- Authority
- MA
- Morocco
- Prior art keywords
- pirlindole
- pharmaceutically acceptable
- acceptable salts
- enantiomers
- medicine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
L'invention concerne des sels pharmaceutiquement acceptables de composés de (r)-pirlindole et de (s)-pirlindole énantiomériquement purs, qui présentent un profil de biodisponibilité acrrue et se destinent à un usage médical.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/PT2014/000026 WO2015171002A1 (fr) | 2014-05-09 | 2014-05-09 | Sels pharmaceutiquement acceptables d'énantiomères de pirlindole s'utilisant en médecine |
Publications (2)
Publication Number | Publication Date |
---|---|
MA39450A1 MA39450A1 (fr) | 2017-08-31 |
MA39450B2 true MA39450B2 (fr) | 2021-10-29 |
Family
ID=50819928
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA39450A MA39450B2 (fr) | 2014-05-09 | 2014-05-09 | Sels pharmaceutiquement acceptables d'énantiomères de pirlindole s'utilisant en médecine |
Country Status (18)
Country | Link |
---|---|
US (1) | US10226460B2 (fr) |
EP (2) | EP3831385B1 (fr) |
JP (1) | JP6400121B2 (fr) |
KR (1) | KR102276281B1 (fr) |
CN (1) | CN106413713B (fr) |
AU (1) | AU2014393487B2 (fr) |
CA (1) | CA2948595C (fr) |
EC (1) | ECSP16086196A (fr) |
IL (1) | IL248852B (fr) |
MA (1) | MA39450B2 (fr) |
MX (1) | MX2016014704A (fr) |
NZ (1) | NZ726127A (fr) |
PH (1) | PH12016502235A1 (fr) |
RU (1) | RU2706688C2 (fr) |
SA (1) | SA516380258B1 (fr) |
TN (1) | TN2016000495A1 (fr) |
UA (1) | UA118587C2 (fr) |
WO (1) | WO2015171002A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA116499C2 (uk) * | 2014-05-09 | 2018-03-26 | Текнімеді Сос'Єдаді Текніку-Медісінал С.А. | (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині |
LT3057589T (lt) * | 2014-05-09 | 2017-11-27 | Tecnimede-Sociedade Tecnico-Medicinal, S.A. | (s)-pirlindolas ir jo farmaciniu požiūriu priimtinos druskos, skirti naudoti medicinoje |
EP3392250A1 (fr) * | 2017-04-21 | 2018-10-24 | Tecnimede-Sociedade Tecnico-Medicinal, S.A. | Procedé pour la préparation de l'anneau de pipérazine pour la synthèse de pyrazinocarbazole |
EP3392251A1 (fr) * | 2017-04-21 | 2018-10-24 | Tecnimede-Sociedade Tecnico-Medicinal, S.A. | Procedé pour la préparation des enantiomères de pirlindole et leurs sels |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK170473B1 (da) * | 1985-06-20 | 1995-09-11 | Daiichi Seiyaku Co | S(-)-pyridobenzoxazinforbindelser |
JP2006504795A (ja) * | 2002-10-03 | 2006-02-09 | サイプレス バイオサイエンス, インコーポレイテッド | 神経学的障害を処置するための抗うつ剤の投薬量の段階的な漸増ならびに毎日の分割した投薬 |
EP1688161A1 (fr) | 2004-11-02 | 2006-08-09 | Switch Biotech Aktiengesellschaft | Utilisation du pirlindole dans le traitement des maladies caracterisées par la prolifération des lymphocytes t et/ou par l'hyperproliferation de kerationcytes, notamment la dermatite atopique et le psoriasis |
JP2012512165A (ja) * | 2008-12-11 | 2012-05-31 | バイオヴィスタ,インコーポレイテッド | 四環系ピラジノインドールを用いた多発性硬化症の治療方法 |
WO2014062621A1 (fr) * | 2012-10-15 | 2014-04-24 | Stc.Unm | Traitement de troubles basés sur l'autophagie et compositions pharmaceutiques, tests et kits de diagnostic et de dépistage associés |
CA2948604C (fr) * | 2014-05-09 | 2021-06-15 | Tecnimede Sociedade Tecnico-Medicinal S.A. | Procede d'obtention d'enantiomeres de pirlindole optiquement actifs et de sels de ceux-ci |
UA116499C2 (uk) * | 2014-05-09 | 2018-03-26 | Текнімеді Сос'Єдаді Текніку-Медісінал С.А. | (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині |
LT3057589T (lt) * | 2014-05-09 | 2017-11-27 | Tecnimede-Sociedade Tecnico-Medicinal, S.A. | (s)-pirlindolas ir jo farmaciniu požiūriu priimtinos druskos, skirti naudoti medicinoje |
-
2014
- 2014-05-09 CN CN201480078725.0A patent/CN106413713B/zh active Active
- 2014-05-09 NZ NZ726127A patent/NZ726127A/en unknown
- 2014-05-09 AU AU2014393487A patent/AU2014393487B2/en active Active
- 2014-05-09 MA MA39450A patent/MA39450B2/fr unknown
- 2014-05-09 US US15/309,981 patent/US10226460B2/en active Active
- 2014-05-09 CA CA2948595A patent/CA2948595C/fr active Active
- 2014-05-09 EP EP20198230.3A patent/EP3831385B1/fr active Active
- 2014-05-09 WO PCT/PT2014/000026 patent/WO2015171002A1/fr active Application Filing
- 2014-05-09 JP JP2016567531A patent/JP6400121B2/ja active Active
- 2014-05-09 EP EP14726441.0A patent/EP3139926A1/fr not_active Withdrawn
- 2014-05-09 KR KR1020167031370A patent/KR102276281B1/ko active IP Right Grant
- 2014-05-09 TN TN2016000495A patent/TN2016000495A1/en unknown
- 2014-05-09 UA UAA201611335A patent/UA118587C2/uk unknown
- 2014-05-09 MX MX2016014704A patent/MX2016014704A/es active IP Right Grant
- 2014-05-09 RU RU2016148174A patent/RU2706688C2/ru active
-
2016
- 2016-11-09 PH PH12016502235A patent/PH12016502235A1/en unknown
- 2016-11-09 IL IL248852A patent/IL248852B/en active IP Right Grant
- 2016-11-09 SA SA516380258A patent/SA516380258B1/ar unknown
- 2016-11-09 EC ECIEPI201686196A patent/ECSP16086196A/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20170143710A1 (en) | 2017-05-25 |
KR102276281B1 (ko) | 2021-07-13 |
TN2016000495A1 (en) | 2018-04-04 |
JP6400121B2 (ja) | 2018-10-03 |
CN106413713A (zh) | 2017-02-15 |
AU2014393487A1 (en) | 2016-11-24 |
SA516380258B1 (ar) | 2019-11-04 |
MX2016014704A (es) | 2017-05-23 |
IL248852B (en) | 2020-05-31 |
IL248852A0 (en) | 2017-01-31 |
NZ726127A (en) | 2019-03-29 |
ECSP16086196A (es) | 2017-02-24 |
EP3831385B1 (fr) | 2024-07-10 |
CA2948595C (fr) | 2021-07-13 |
WO2015171002A1 (fr) | 2015-11-12 |
UA118587C2 (uk) | 2019-02-11 |
CN106413713B (zh) | 2020-07-14 |
RU2706688C2 (ru) | 2019-11-20 |
MA39450A1 (fr) | 2017-08-31 |
PH12016502235A1 (en) | 2017-01-09 |
CA2948595A1 (fr) | 2015-11-12 |
AU2014393487B2 (en) | 2020-01-02 |
RU2016148174A3 (fr) | 2018-06-14 |
EP3139926A1 (fr) | 2017-03-15 |
EP3831385A1 (fr) | 2021-06-09 |
KR20170002433A (ko) | 2017-01-06 |
JP2017514882A (ja) | 2017-06-08 |
US10226460B2 (en) | 2019-03-12 |
RU2016148174A (ru) | 2018-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123810T1 (el) | Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα | |
PH12016501355A1 (en) | Bicyclic heterocyclic derivatives as bromodomain inhibitors | |
BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
EA201790271A1 (ru) | Ингибиторы гликозидазы | |
UY35834A (es) | Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon | |
EP3970712A3 (fr) | Formes posologiques solides orales de 2r, 6r-hydroxynorkétamine ou leurs dérivés | |
EA201691600A1 (ru) | Дигидропиридиноновые ингибиторы mgat2 для применения в лечении метаболических нарушений | |
MX2017016802A (es) | Formulaciones farmaceuticas. | |
MX2019006721A (es) | Tratamiento para la colangitis biliar primaria. | |
CY1124907T1 (el) | Αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα | |
SV2016005313A (es) | Derivados de carboxamida | |
EP3405211A4 (fr) | Octréotide par voie orale pour le traitement de maladies | |
PH12016501751A1 (en) | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder | |
PH12018500859A1 (en) | Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone for the treatment of parkinson`s disease | |
MA39450B2 (fr) | Sels pharmaceutiquement acceptables d'énantiomères de pirlindole s'utilisant en médecine | |
GB2587172B (en) | Pyronaridine or pharmaceutically acceptable salts thereof for the treatment of cancer | |
PL3285755T3 (pl) | Chlorowodorek kreatyny do leczenia choroby Huntingtona | |
PH12017501955A1 (en) | Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease | |
MX2015013048A (es) | Forma cristalina de un compuesto ansiolitico. | |
HK1259373A1 (zh) | 用於治療糖尿病的藥物製劑 | |
MX2017014301A (es) | Composiciones y metodos para el tratamiento o prevencion de hipertension pulmonar. | |
GB2501050A (en) | Pharmaceutical compositons of immunosuppressants | |
EA201991141A1 (ru) | Усилители bmp | |
TH1601007484A (th) | สารประกอบเฮเทอโรแอริลสำหรับการยับยั้งไคเนส | |
EA201692164A1 (ru) | Лекарственное средство для лечения пациентов с тиннитусом |